539 related articles for article (PubMed ID: 15890503)
1. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo.
Varma MV; Panchagnula R
Eur J Pharm Sci; 2005; 25(4-5):445-53. PubMed ID: 15890503
[TBL] [Abstract][Full Text] [Related]
2. Enhanced oral bioavailability of paclitaxel by D-alpha-tocopheryl polyethylene glycol 400 succinate in mice.
Ho PY; Yeh TK; Yao HT; Lin HL; Wu HY; Lo YK; Chang YW; Chiang TH; Wu SH; Chao YS; Chen CT
Int J Pharm; 2008 Jul; 359(1-2):174-81. PubMed ID: 18513900
[TBL] [Abstract][Full Text] [Related]
3. Stable phosphatidylcholine-bile salt mixed micelles enhance oral absorption of paclitaxel: preparation and mechanism in rats.
Zhao Y; Cui Y; Li Y; Li L
J Drug Target; 2014 Dec; 22(10):901-12. PubMed ID: 25077358
[TBL] [Abstract][Full Text] [Related]
4. Co-treatment with grapefruit juice inhibits while chronic administration activates intestinal P-glycoprotein-mediated drug efflux.
Panchagnula R; Bansal T; Varma MV; Kaul CL
Pharmazie; 2005 Dec; 60(12):922-7. PubMed ID: 16398269
[TBL] [Abstract][Full Text] [Related]
5. Prediction of in vivo intestinal absorption enhancement on P-glycoprotein inhibition, from rat in situ permeability.
Varma MV; Panchagnula R
J Pharm Sci; 2005 Aug; 94(8):1694-704. PubMed ID: 15986467
[TBL] [Abstract][Full Text] [Related]
6. Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability.
Yu L; Bridgers A; Polli J; Vickers A; Long S; Roy A; Winnike R; Coffin M
Pharm Res; 1999 Dec; 16(12):1812-7. PubMed ID: 10644067
[TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein and surfactants: effect on intestinal talinolol absorption.
Bogman K; Zysset Y; Degen L; Hopfgartner G; Gutmann H; Alsenz J; Drewe J
Clin Pharmacol Ther; 2005 Jan; 77(1):24-32. PubMed ID: 15637528
[TBL] [Abstract][Full Text] [Related]
8. Effects of silibinin, inhibitor of CYP3A4 and P-glycoprotein in vitro, on the pharmacokinetics of paclitaxel after oral and intravenous administration in rats.
Lee CK; Choi JS
Pharmacology; 2010; 85(6):350-6. PubMed ID: 20523105
[TBL] [Abstract][Full Text] [Related]
9. Rational design of hybrid nanomicelles integrating mucosal penetration and P-glycoprotein inhibition for efficient oral delivery of paclitaxel.
Lian H; He Z; Meng Z
Colloids Surf B Biointerfaces; 2017 Jul; 155():429-439. PubMed ID: 28463810
[TBL] [Abstract][Full Text] [Related]
10. P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel.
Kimura Y; Aoki J; Kohno M; Ooka H; Tsuruo T; Nakanishi O
Cancer Chemother Pharmacol; 2002 Apr; 49(4):322-8. PubMed ID: 11914912
[TBL] [Abstract][Full Text] [Related]
11. Enhanced oral bioavailability of paclitaxel formulated in vitamin E-TPGS emulsified nanoparticles of biodegradable polymers: in vitro and in vivo studies.
Zhao L; Feng SS
J Pharm Sci; 2010 Aug; 99(8):3552-60. PubMed ID: 20564384
[TBL] [Abstract][Full Text] [Related]
12. Oral administration of paclitaxel with pegylated poly(anhydride) nanoparticles: permeability and pharmacokinetic study.
Zabaleta V; Ponchel G; Salman H; Agüeros M; Vauthier C; Irache JM
Eur J Pharm Biopharm; 2012 Aug; 81(3):514-23. PubMed ID: 22516136
[TBL] [Abstract][Full Text] [Related]
13. A novel drug-phospholipid complex loaded micelle for baohuoside I enhanced oral absorption: in vivo and in vivo evaluations.
Jin X; Zhang ZH; Sun E; Tan XB; Zhu FX; Jia XB
Drug Dev Ind Pharm; 2013 Sep; 39(9):1421-30. PubMed ID: 23057574
[TBL] [Abstract][Full Text] [Related]
14. The mechanism of enhancement on oral absorption of paclitaxel by N-octyl-O-sulfate chitosan micelles.
Mo R; Jin X; Li N; Ju C; Sun M; Zhang C; Ping Q
Biomaterials; 2011 Jul; 32(20):4609-20. PubMed ID: 21440934
[TBL] [Abstract][Full Text] [Related]
15. pH-dependent functional activity of P-glycoprotein in limiting intestinal absorption of protic drugs: kinetic analysis of quinidine efflux in situ.
Varma MV; Panchagnula R
J Pharm Sci; 2005 Dec; 94(12):2632-43. PubMed ID: 16258992
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting efflux with novel non-ionic surfactants: Rational design based on vitamin E TPGS.
Wempe MF; Wright C; Little JL; Lightner JW; Large SE; Caflisch GB; Buchanan CM; Rice PJ; Wacher VJ; Ruble KM; Edgar KJ
Int J Pharm; 2009 Mar; 370(1-2):93-102. PubMed ID: 19100824
[TBL] [Abstract][Full Text] [Related]
17. Improved oral bioavailability of fexofenadine hydrochloride using lipid surfactants: ex vivo, in situ and in vivo studies.
Eedara BB; Veerareddy PR; Jukanti R; Bandari S
Drug Dev Ind Pharm; 2014 Aug; 40(8):1030-43. PubMed ID: 23738504
[TBL] [Abstract][Full Text] [Related]
18. Amphiphilic carboxymethyl chitosan-quercetin conjugate with P-gp inhibitory properties for oral delivery of paclitaxel.
Wang X; Chen Y; Dahmani FZ; Yin L; Zhou J; Yao J
Biomaterials; 2014 Aug; 35(26):7654-65. PubMed ID: 24927684
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS).
Dintaman JM; Silverman JA
Pharm Res; 1999 Oct; 16(10):1550-6. PubMed ID: 10554096
[TBL] [Abstract][Full Text] [Related]
20. An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine.
Johnson BM; Charman WN; Porter CJ
AAPS PharmSci; 2002; 4(4):E40. PubMed ID: 12646011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
